Anumana
Under the multiyear strategic partnership Anumana will conduct a clinical-validation trial and seek FDA De Novo classification for the algorithm.
NeuTrace focused on developing in-procedure AI tools for electrophysiology.
The partnership will focus on software that uses ECGs to find left ventricular dysfunction and atherosclerotic cardiovascular disease.
Also: Anumana receives FDA Breakthrough Device Designation for its ECG-based algorithm designed for early detection of pulmonary hypertension, and AI-enabled imaging companies Aidoc and Gleamer partner.